GHK-Cu

Peptide

Copper tripeptide-1

Recorded history of GHK-Cu — FDA records, PCAC review history, and state overlays. Each entry links to its source; entries marked reported rest on reported sources; source classification alone does not authenticate a vote tally.

Planned review

Eligibility not established here

FDA intends to review GHK-Cu at a further Pharmacy Compounding Advisory Committee meeting — by the end of February 2027 (exact date not yet posted). FDA PCAC ↗

Recorded status is not an eligibility determination. PCAC recommendations are advisory. Category 1 is a nomination under FDA evaluation, distinct from the final 503A Bulks List established by rulemaking. FDA’s January 2025 interim policy describes conditional enforcement discretion, not FDA approval or unconditional permission. Its Category 1 conditions include manufacturer registration, a valid certificate of analysis and all other applicable 503A conditions; that policy does not apply to Category 2. Assess the exact substance, form and route against the applicable monograph, approved-drug-component, final-list and interim-policy provisions.

FDA January 2025 interim guidance ↗

FDA’s May 14, 2026 nomination document lists GHK-Cu except for injectable routes in Category 1, following a May 5 clarification of the withdrawal. Injectable GHK-Cu is discussed separately among withdrawn nominations with safety concerns. The non-injectable listing does not establish injectable eligibility or unconditional compounding permission.

FDA May 14, 2026 nomination document ↗

Tracker collector’s last successful poll: not available on this public page. The aggregate polling signal on the tracker index covers multiple sources.

Per-substance authority reconciliation: no documented date is provided here. A recent source event or poll does not establish complete coverage of FDA updates.

Source-event dates and recent source polls do not establish that each substance’s current eligibility has been reverified.

We do not sell, source, or supply GHK-Cu. This is a monitoring record from public government sources — not a product, and not advice.

Federal history

No MSR event recorded in the published federal history for GHK-Cu. This is a gap in this tracker’s record, not evidence that no federal position or source exists.

State overlays

No MSR event recorded in the published state history for GHK-Cu. State boards hold independent authority; legislation is monitored via LegiScan and board positions are added as they are verified.

Track GHK-Cu changes

Get the free weekly Brief — FDA and state moves on peptide & GLP-1 compounding, with the source and the date. Members are alerted for their states as soon as a change is published.

Get the free Brief →

← All substances · Informational monitoring from public government sources — not legal or medical advice. No efficacy claims.

Get regulatory changes as they publish

We scan all 50 state legislatures daily, plus the FDA and the Federal Register. Free weekly Brief — what changed, in plain language, with the source.

Free · unsubscribe in one click · we never sell your address